| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 554.35% | HC Wainwright & Co. | → $124 | Reiterates | Buy → Buy |
| 07/06/2023 | 554.35% | HC Wainwright & Co. | $124 → $124 | Reiterates | Buy → Buy |
| 05/11/2023 | 554.35% | HC Wainwright & Co. | → $124 | Reiterates | Buy → Buy |
| 05/09/2023 | 554.35% | HC Wainwright & Co. | → $124 | Reiterates | → Buy |
| 03/06/2023 | 554.35% | HC Wainwright & Co. | → $124 | Reiterates | → Buy |
| 01/24/2023 | 554.35% | HC Wainwright & Co. | → $124 | Reiterates | → Buy |
| 08/11/2022 | 132.19% | B. Riley Securities | $58 → $44 | Maintains | Buy |
| 01/24/2022 | 279.95% | B. Riley Securities | $108 → $72 | Maintains | Buy |
| 07/20/2021 | 554.35% | HC Wainwright & Co. | $97 → $124 | Maintains | Buy |
| 06/23/2021 | 485.75% | B. Riley Securities | $78 → $111 | Maintains | Buy |
| 04/27/2021 | 311.61% | B. Riley Securities | → $78 | Initiates Coverage On | → Buy |
| 03/17/2021 | 480.47% | JonesTrading | → $110 | Initiates Coverage On | → Buy |
| 02/23/2021 | 411.87% | HC Wainwright & Co. | $66 → $97 | Maintains | Buy |
| 02/16/2021 | 322.16% | Maxim Group | $14 → $80 | Maintains | Buy |
| 02/16/2021 | 248.28% | HC Wainwright & Co. | $20 → $66 | Maintains | Buy |
| 10/23/2020 | 26.65% | Cantor Fitzgerald | → $24 | Initiates Coverage On | → Overweight |
| 09/23/2020 | 5.54% | HC Wainwright & Co. | → $20 | Upgrades | Neutral → Buy |
| 09/14/2020 | -26.12% | Maxim Group | → $14 | Upgrades | Hold → Buy |
| 05/18/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/08/2020 | -15.57% | HC Wainwright & Co. | $6 → $16 | Reiterates | → Buy |
| 12/06/2019 | -68.34% | HC Wainwright & Co. | $3 → $6 | Reiterates | → Buy |
| 08/01/2019 | -84.17% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 06/25/2019 | -84.17% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
What is the target price for Cassava Sciences (SAVA)?
The latest price target for Cassava Sciences (NASDAQ: SAVA) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $124.00 expecting SAVA to rise to within 12 months (a possible 554.35% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cassava Sciences (SAVA)?
The latest analyst rating for Cassava Sciences (NASDAQ: SAVA) was provided by HC Wainwright & Co., and Cassava Sciences reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Cassava Sciences (SAVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cassava Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cassava Sciences was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Cassava Sciences (SAVA) correct?
While ratings are subjective and will change, the latest Cassava Sciences (SAVA) rating was a reiterated with a price target of $0.00 to $124.00. The current price Cassava Sciences (SAVA) is trading at is $18.95, which is within the analyst's predicted range.
